SCHEMBL14883263

SCHEMBL14883263

CC(C)c1ccc(F)cc1-c1ncccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP1 O94782 2/20 0.39
▸ CASP6 P55212 2/20 0.38
▸ HRH4 Q9H3N8 1/20 0.37
▸ RPS6KA3 P51812 1/20 0.36
▸ P2RY1 P47900 1/20 0.36
▸ ALOX5AP P20292 2/20 0.36
▸ FEN1 P39748 2/20 0.36
▸ HCRTR1 O43613 3/20 0.35
▸ HCRTR2 O43614 3/20 0.35
▸ TDO2 P48775 1/20 0.35
▸ NPY5R Q15761 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ CHRM4 P08173 1/20 0.34
▸ CHRM5 P08912 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34
▸ MAPK14 Q16539 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14883264 0.86 HRH4 (0.40) USP1CASP6HRH4RPS6KA3P2RY1
SCHEMBL11994401 0.76 ALOX5AP (0.43) RPS6KA3ALOX5APFEN1BRD4
SCHEMBL14886183 0.76 NISCH (0.49) CASP6HCRTR1HCRTR2TDO2MAPK14
SCHEMBL10094408 0.75 RPS6KA3 (0.46) RPS6KA3MAPK14
SCHEMBL31517722 0.75 CASP6 (0.43) CASP6NPY5RIDH1
SCHEMBL12444953 0.75 PIP4K2C (0.47) USP1
SCHEMBL23419417 0.74 PTGS1 (0.39) TDO2RECQLCHRM3MAPK14
SCHEMBL10094404 0.73 TDO2 (0.50) RPS6KA3TDO2
SCHEMBL26511855 0.73 TYK2 (0.36) ALOX5APFEN1
SCHEMBL27021631 0.73 NPC1 (0.45) CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9156819-B2 2-pyridyloxy-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2015-10-13 — — US disclosed
US-9156819-B2 2-pyridyloxy-4-nitrile orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2015-10-13 — — US disclosed
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2013-04-25 — — US disclosed
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2013-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102619-A1 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NTSR2 USP1 2950/4885CASP6 3872/4885HRH4 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback